risks of glp-1 INFOGRAPHIC: The Hidden Weight Loss Medications GLP-1 Agonists In Obesity

Never discontinue prescribed medications without medical consultation , as abrupt cessation may compromise diabetes control

Our previous report provided a more detailed analysis of the continued growth trend in their uptake

These therapeutic agents contribute to improvements in key cardiovascular risk factors, including reductions in body weight, blood pressure, and glycaemic variability, all of which are independently associated with decreased cardiovascular risk [4, 5]

Meanwhile, North America has dominated the GLP-1 agonists weight-loss drug market, accounting for nearly 76% of overall revenue

Accessed 22/2/2025 Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB

Ionization issues: GLP-1 peptides produce multiple charge states and suffer from low ionization efficiency and ion suppression from TFA or excipients